Processa Pharmaceuticals (PCSA) Operating Expenses (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Operating Expenses came in at $4.0 million in Q1 2026, up 13.83% YoY from $3.5 million in Q1 2025, and up 8.26% on a QoQ basis from $3.7 million in Q4 2025.
Processa Pharmaceuticals (PCSA) Operating Expenses (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 15 years of Operating Expenses data on file, last reported at $4.0 million in Q1 2026.
- Quarterly Operating Expenses rose 13.83% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.1 million (up 18.7% YoY) and the FY2025 annual result came in at $16.8 million, up 19.54% from the prior year.
- Operating Expenses climbed to $4.0 million in Q1 2026, from $3.7 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $6.1 million in Q3 2022 to a low of $2.2 million in Q3 2023.
- A 5-year average of $3.7 million and a median of $3.5 million in 2025 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses jumped 97.91% — and 2023, when it tumbled 64.21%.
- Tracing PCSA's Operating Expenses over 5 years: stood at $5.8 million in 2022, then slumped by 57.42% to $2.5 million in 2023, then advanced by 10.74% to $2.7 million in 2024, then soared by 35.37% to $3.7 million in 2025, then climbed by 8.26% to $4.0 million in 2026.
- The last three Operating Expenses figures came in at $4.0 million (Q1 2026), $3.7 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Processa Pharmaceuticals | 5.93 Mn | 5.93 Mn | - | 2.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.01 Mn |
| Dec 31, 2025 | 3.70 Mn |
| Sep 30, 2025 | 3.49 Mn |
| Jun 30, 2025 | 3.95 Mn |
| Mar 31, 2025 | 3.52 Mn |
| Dec 31, 2024 | 2.73 Mn |
| Sep 30, 2024 | 3.42 Mn |
| Jun 30, 2024 | 3.08 Mn |
| Mar 31, 2024 | 2.81 Mn |
| Dec 31, 2023 | 2.47 Mn |
| Sep 30, 2023 | 2.17 Mn |
| Jun 30, 2023 | 2.71 Mn |
| Mar 31, 2023 | 4.11 Mn |
| Dec 31, 2022 | 5.80 Mn |
| Sep 30, 2022 | 6.06 Mn |
| Jun 30, 2022 | 5.17 Mn |
| Mar 31, 2022 | 3.23 Mn |
| Dec 31, 2021 | 3.37 Mn |
| Sep 30, 2021 | 3.06 Mn |
| Jun 30, 2021 | 2.94 Mn |